Bank of America’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.47M | Buy |
237,004
+509
| +0.2% | +$8.12K | ﹤0.01% | 3737 |
|
|
2025
Q4 | $1.82M | Buy |
236,495
+84,529
| +56% | +$667K | ﹤0.01% | 4137 |
|
|
2025
Q3 | $1.12M | Buy |
151,966
+19,237
| +14% | +$98.5K | ﹤0.01% | 5253 |
|
|
2025
Q2 | $531K | Buy |
132,729
+34,180
| +35% | +$124K | ﹤0.01% | 5672 |
|
|
2025
Q1 | $313K | Buy |
98,549
+1,568
| +2% | +$7.39K | ﹤0.01% | 5921 |
|
|
2024
Q4 | $519K | Buy |
96,981
+96,572
| +23,612% | +$721K | ﹤0.01% | 5508 |
|
|
2024
Q3 | $2.16K | Buy |
409
+17
| +4% | +$61 | ﹤0.01% | 7116 |
|
|
2024
Q2 | $713 | Buy |
+392
| New | +$730 | ﹤0.01% | 7287 |
|
|
2024
Q1 | – | Sell |
-22
| Closed | -$39 | – | 7803 |
|
|
2023
Q4 | $39 | Sell |
22
-3,150
| -99% | -$4.61K | ﹤0.01% | 7546 |
|
|
2023
Q3 | $4.63K | Sell |
3,172
-1,907
| -38% | -$4.03K | ﹤0.01% | 7012 |
|
|
2023
Q2 | $11.6K | Buy |
+5,079
| New | +$10.6K | ﹤0.01% | 6822 |
|
|
2023
Q1 | – | Sell |
-70
| Closed | -$60 | – | 7875 |
|
|
2022
Q4 | $60 | Sell |
70
-184
| -72% | -$163 | ﹤0.01% | 7766 |
|
|
2022
Q3 | $0 | Sell |
254
-209
| -45% | -$199 | ﹤0.01% | 7887 |
|
|
2022
Q2 | $0 | Sell |
463
-1,067
| -70% | -$1.31K | ﹤0.01% | 8064 |
|
|
2022
Q1 | $2K | Sell |
1,530
-798
| -34% | -$1.46K | ﹤0.01% | 8034 |
|
|
2021
Q4 | $6K | Buy |
+2,328
| New | +$9.03K | ﹤0.01% | 7787 |
|
|
2021
Q3 | – | Sell |
-92
| Closed | – | – | 8140 |
|
|
2021
Q2 | $0 | Sell |
92
-9,844
| -99% | -$27.1K | ﹤0.01% | 7796 |
|
|
2021
Q1 | $31K | Buy |
+9,936
| New | +$35.9K | ﹤0.01% | 6770 |
|
|
2020
Q2 | – | Sell |
-3,619
| Closed | -$8K | – | 6866 |
|
|
2020
Q1 | $8K | Sell |
3,619
-19,192
| -84% | -$77.9K | ﹤0.01% | 6411 |
|
|
2019
Q4 | $124K | Sell |
22,811
-24,616
| -52% | -$86.1K | ﹤0.01% | 5896 |
|
|
2019
Q3 | $143K | Sell |
47,427
-30,821
| -39% | -$129K | ﹤0.01% | 5860 |
|
|
2019
Q2 | $293K | Buy |
78,248
+6,665
| +9% | +$26.1K | ﹤0.01% | 5423 |
|
|
2019
Q1 | $287K | Sell |
71,583
-8,698
| -11% | -$36.7K | ﹤0.01% | 5337 |
|
|
2018
Q4 | $294K | Buy |
80,281
+19,451
| +32% | +$133K | ﹤0.01% | 5258 |
|
|
2018
Q3 | $522K | Buy |
60,830
+6,813
| +13% | +$68.1K | ﹤0.01% | 4919 |
|
|
2018
Q2 | $593K | Buy |
54,017
+1,358
| +3% | +$15.2K | ﹤0.01% | 4800 |
|
|
2018
Q1 | $607K | Buy |
52,659
+44,970
| +585% | +$425K | ﹤0.01% | 4699 |
|
|
2017
Q4 | $79K | Buy |
7,689
+7,298
| +1,866% | +$93.4K | ﹤0.01% | 5849 |
|
|
2017
Q3 | $6K | Buy |
391
+390
| +39,000% | +$5.4K | ﹤0.01% | 6669 |
|
|
2017
Q2 | $0 | Sell |
1
-2,781
| -100% | -$29.7K | ﹤0.01% | 6959 |
|
|
2017
Q1 | $58K | Sell |
2,782
-82
| -3% | -$1.28K | ﹤0.01% | 5854 |
|
|
2016
Q4 | $41K | Buy |
2,864
+530
| +23% | +$8.06K | ﹤0.01% | 6016 |
|
|
2016
Q3 | $39K | Buy |
2,334
+75
| +3% | +$1.08K | ﹤0.01% | 5827 |
|
|
2016
Q2 | $32K | Buy |
+2,259
| New | +$30.5K | ﹤0.01% | 6034 |
|
Other funds holding CRVS
O
ASP
VCM
VC
DTC
Bank of America's CRVS Position: Q1 2026 in Review
Bank of America increased its Corvus Pharmaceuticals (CRVS) stake by 0.22% in Q1 2026, buying an estimated $8.12K and bringing the position to 237,004 shares worth $3.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3737.
Bank of America first reported a position in CRVS in Q2 2016 and has held it in 34 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.
- Bank of America held 237,004 shares of Corvus Pharmaceuticals worth $3.47M as of Q1 2026.
- Bank of America bought 509 Corvus Pharmaceuticals shares in Q1 2026, an estimated $8.12K.
- Corvus Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3737 holding.
- Bank of America first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 34 quarters since.
- 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.